Navigation Links
U.S. District Court Finds the FDA's Actions on Plan B(R) Tainted by Politics
Date:3/23/2009

WASHINGTON, March 23 /PRNewswire/ -- Today a U.S. District Court ruled that the Food and Drug Administration (FDA) allowed politics to taint their decision to make Plan B(R) available over-the-counter (OTC) for individuals age 18 and older. The judge recognized that the FDA gave into political pressure and did not rely on the sound science that supported making Plan B available without a prescription for all age groups. Calling the FDA's procedure for approving the drug "capricious" and "arbitrary," the court ordered the FDA to reconsider its decisions regarding the Plan B switch to OTC use and ordered the FDA to permit Plan B's availability to 17 year olds without a prescription beginning in 30 days.

"This ruling validates what we have known all along - politicians trumped the scientists when it came to the FDA's handling of Plan B," said Kirsten Moore, President and CEO of the Reproductive Health Technologies Project. "Plan B is a safe and effective back-up contraceptive method that gives women of all ages an option to prevent unintended pregnancy. We urge the FDA and Duramed to work together to lift the unnecessary age restriction and put Plan B on pharmacy shelves to make timely access a reality for anyone who needs it."

This ruling comes in response to a lawsuit filed by the Center for Reproductive Rights against the FDA for its failure to make emergency contraception Plan B available over-the-counter. The lawsuit claimed that the FDA broke its own rules and regulations, ignored medical consensus, as well as the expertise of its own scientists and advisory committees by holding Plan B to an arbitrarily higher standard than other OTC products. The plaintiffs asked the court to order the FDA to make Plan B available over-the-counter for women of all ages.

Plan B is an FDA-approved, back-up birth control method that can prevent pregnancy in the first few days after sex. Containing a concentrated dose of the progestin hormone found in daily birth control pills, Plan B can reduce the risk of pregnancy by up to 89 percent when taken within 72 hours of sexual intercourse (the sooner a woman takes it, the more effective it is). Critics have argued that increased access to Plan B would lead to promiscuity or other risky health behaviors but these concerns are misplaced. Real world experience with EC and other contraceptives show that reducing barriers to access is important but not sufficient when it comes to reducing unintended pregnancy. Access must be coupled with information and education to help individuals make healthy choices throughout their lifetime.

For more information including a complete timeline of the approval process for Plan B OTC please visit: http://www.rhtp.org


'/>"/>
SOURCE Reproductive Health Technologies Project
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Integrated Medical Center and Critical Access Hospital for San Juan County Hospital District
2. Wayne County Community College District Presents Second Annual Child Car Seat Check Program
3. HealthLeaders-InterStudy Offers District Survival Kit to Arm Pharmaceutical Sales Teams With Local-Level Managed Care Market Intelligence
4. Philadelphia School District and Independence Blue Cross Partner to Improve Student Wellness and Reduce Childhood Obesity
5. Lee County School District online wellness program inspires employees to walk 200 million steps in 2 months
6. Sacramento Mother Dee Dee Abdur-Rahim and Deputy District Attorney Robin Shakely Join the American Lung Associations Faces of Influenza Campaign to Promote Annual Vaccination
7. Innovative Wellness Project Launched in Four Maine School Districts
8. iCRco Lands CR Contract with Thu Duc District Hospital in Vietnam
9. U.S. District Court in Delaware Reinstates Damage Awards to Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation
10. Watson Announces District Court Ruling in Naproxen Sodium Patent Suit
11. New Research Covers Current Trends and Future Directions of the High Performing Pharmaceutical District Sales Managers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... Marina del Rey, CA (PRWEB) , ... August ... ... provider of revenue cycle management (RCM) solutions, announced recently the availability of a ... the HIM community in appreciation for their service to the healthcare industry. E/M ...
(Date:8/22/2017)... , ... August 22, 2017 , ... “To Walk Away”: ... on a B17 bomber named Edward Koontz. “To Walk Away” is the creation of ... who has published over two hundred manuscripts in chemistry and religion, as well as ...
(Date:8/22/2017)... ... , ... “Covert Awakening”: Walid’s spiritual journey from Islamic terrorist ... a consultant for the Intelligence Community. For more than ten years, she ... region. Julianne has written hundreds of reports for the US government analyzing ...
(Date:8/22/2017)... ... ... TopConsumerReviews.com recently gave a best-in-class 5-star rating to Energy NADH, a leader ... modern life continually makes more demands on time and energy, people are finding it ... in vicious high/low cycles and can also cause long term health issues. More people ...
(Date:8/21/2017)... ... 22, 2017 , ... PracticeMatch, a company that provides online resources , ... and advanced practitioners like nurse practitioners and physician assistants , will ... of this year. The online career fairs will allow job seekers to connect with ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... Tenn. , July 31, 2017 Three Tru-D SmartUVC ... Yongsan, South Korea . Tru-D, short for "Total Room ... and operating rooms after an environmental services (ES) professional cleans the area ... ... "Although the ...
(Date:7/27/2017)... WARSAW, Ind., July 27, 2017  Zimmer Biomet Holdings, ... the quarter ended June 30, 2017.  The Company reported ... of 1.1% over the prior year period, and an ... approximately 240 basis points of contribution from the LDR ... from the second quarter of 2016, or 0.3% on ...
(Date:7/26/2017)... 26, 2017 Sancilio Pharmaceuticals Company, Inc. (SPCI) ... trial evaluating Altemia TM , an oral therapy for ... Cell Disease (SCD). The SCOT Trial, is a double-blind, ... safety of Altemia TM in pediatric patients aged ... IND 125274. "The ...
Breaking Medicine Technology: